SVAX

SVAX is an Italian biotechnology company specializing in the development of next-generation cancer vaccines using Outer Membrane Vesicles (OMVs). Spun off from the University of Trento, the company leverages a proprietary platform to engineer Gram-negative bacteria that release OMVs decorated with specific tumor antigens. These vesicles act as both the delivery vehicle and a potent adjuvant, triggering robust T-cell-mediated immune responses against tumors. SVAX's approach is designed to be highly versatile, allowing for the rapid development of both personalized and off-the-shelf immunotherapies. The company is currently advancing its lead oncology candidates through pre-clinical stages with the goal of entering clinical trials. SVAX is supported by prominent investors including Indaco Venture Partners and CDP Venture Capital.